Open Access Open Access  Restricted Access Subscription or Fee Access

Validation of a new risk assessment tool: The Brief Risk Questionnaire

Ted Jones, PhD, Samantha Lookatch, MA, Todd Moore, PhD


Opioids remain a common method of treating chronic pain conditions despite some controversy. In an effort to address some of the risks of opioid medications, opioid risk assessment has become a standard of care when opioids are used to treat a chronic pain condition. Research to date has found that many currently available patient-completed written questionnaires are relatively poor at identifying which patients will engage in medication aberrant behavior in the future. Clinical interview techniques have been found to provide better prediction, but practitioners often prefer the convenience of patient-completed tools. In this study, a new brief patient-completed risk tool, the Brief Risk Questionnaire (BRQ), was created and compared with a structured clinical interview and two commonly used patient-completed risk assessment tools: the Opioid Risk Tool (ORT) and Screener and Opioid Assessment for Patients with Pain-Revised (SOAPP-R). The different risk assessment measures were administered to 454 patients at a pain clinic and their prediction of medication aberrant behavior at 6-month follow-up was compared. Results found that the BRQ was able to predict future medication aberrant behavior better than the other two patient-completed risk measures and almost as well overall as a structured clinical interview rating system. This study indicates that the BRQ could be a useful new tool for clinicians in conducting opioid risk assessment.


opioid risk assessment, chronic pain, medication aberrant behavior

Full Text:



Federation of State Medical Boards (FSMB): Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain. Washington, DC: The Federation, 2013.

Noble M, Treadwell JR, Tregear SJ, et al.: Cochrane Database of Systematic Reviews, Issue 1. Long-term Opioid Management for Chronic Noncancer Pain. New York, NY: The Cochrane Collaborative, John Wiley & Sons, Ltd, 2010.

Rosenblum A, Marsch LA, Joseph H, et al.: Opioids and the treatment of chronic pain: Controversies, current status, and future directions. Exp Clin Psychopharm. 2008; 16(5): 405-416.

Office of National Drug Control Policy (ONDCP): Epidemic: Responding to America's Prescription Drug Abuse Crisis. Washington, DC: Executive Office of the President, The White House, 2011.

Chou R, Fanciullo GJ, Fine PG, et al.: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2): 113-130.

Gourley DL, Heit HA, Almahrezi A: Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Med. 2005; 6: 107-112.

Gourley DL, Heit HA: Universal precautions revisited: Managing the inherited pain patient. Pain Med. 2009; 10(suppl 2): S115-S123.

Katz NP, Adams EH, Benneyan JC, et al.: Foundations of opioid risk management. Clin J Pain. 2007; 23(2): 103-118.

Webster LR, Webster RM: Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the Opioid Risk Tool. Pain Med. 2005; 6(6): 432-442.

Adams LL, Gatchel RJ, Robinson RC, et al.: Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients. J Pain Symptom Manage. 2004; 27(5): 440-459.

Belgrade MJ, Schamber CD, Lindgren BR: The DIRE score: Predicting outcomes of opioid prescribing for chronic pain. J Pain. 2006; 7(9): 671-681.

Butler SF, Budman SH, Fernandez K, et al.: Validation of a screener and opioid assessment measure for patients with chronic pain. Pain. 2004; 112(1-2): 65-75.

Butler SF, Fernandez K, Benoit C, et al.: Validation of the Revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008; 9(4): 360-372.

Chou R, Fanciullo GJ, Fine PG, et al.: Opioids for chronic noncancer pain: Prediction and identification of aberrant drug-related behaviors: A review of the evidence for an American Pain Society and American Academy of Pain Medicine Clinical Practice Guidelines. J Pain. 2009; 10(2): 131-146.

Moore TM, Jones T, Browder JH, et al.: A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids of chronic pain management. Pain Med. 2009; 10(8): 1426-1433.

Jones T, Moore TM, Levy J, et al.: A comparison of various risk screening methods for patients receiving opioids for chronic pain management. Clin J Pain. 2012; 28(2): 93-100.

Witkin LR, Diskina D, Fernandes S, et al.: Usefulness of the Opioid Risk Tool to predict aberrant drug-related behavior in patients receiving opioids for the treatment of chronic pain. J Opioid Manag. 2013; 9(3): 177-187.

Jones T, Moore TM: Preliminary data on a new risk assessment tool: The Brief Risk Interview. J Opioid Manag. 2013; 9(1): 19-27.

Jones T, Lookatch S, Grant P, et al.: Further validation of an opioid risk assessment tool: The Brief Risk Interview. J Opioid Manag. 2014; 10(5): 353-364.

Chabal C, Erjavec MK, Jacobson L, et al.: Prescription opiate abuse in a chronic pain patients: Clinical criteria, incidence, and predictors. Clin J Pain. 1997; 1: 150-155.

Michna E, Ross EL, Nynes WL, et al.: Predicting aberrant drug behavior in patients treated for chronic pain: Importance of abuse history. J Pain Symptom Manage. 2004; 28: 250-258.



  • There are currently no refbacks.